France Blood Screening Market to 2032
Overview
The France Blood Screening Market is expected to reach a 221.16 USD Million by 2032 and is projected to grow at a CAGR of 12.73% from 2025 to 2032.
Revenue, 2024 (USD Million)
105.27
Forecast, 2032 (USD Million)
221.16
CAGR, 2024 - 2032
12.73%
Report Coverage
France
France Blood Screening Market 2018-2032 USD Million
France Blood Screening Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 105.27 USD Million
- Projected Market Size (2032): 221.16 USD Million
- CAGR (2025-2032): 12.73%
Key Findings of France Blood Screening Market
- The France Blood Screening Market was valued at 105.27 USD Million in 2024.
- The France Blood Screening Market is likely to grow at a CAGR of 12.73% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Reagents & Kits in Products & Services Segment accounted for the largest share of the market with a revenue of 51.46 USD Million
- The fastest growing segment Oncology in Disease Type Segment grew Fastest with a CAGR of 13.71% during the forecast period from 2024 to 2032.
France Blood Screening Market Scope
France Blood Screening Market Segmentation & Scope
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Rapid Tests
- Enzyme-Linked Immunosorbent Assay (ELISA)
France Blood Screening Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 105.27 USD Million |
| Market Value in 2032 | 221.16 USD Million |
| CAGR (2025-2032) | 12.73% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Disease Type,End User,Products & Services,Technology |
Regional Insights:
-
Leading Market (2024-2032): France, leading in terms of revenue 105.27 USD Million in 2024
- Key Country: France, leading in terms of revenue with value of 105.27 USD Million in 2024.
Segments and Scope
-
France Blood Screening Market to 2032, By Disease Type
- Oncology is the largest segment in France Blood Screening Market to 2032 with a revenue of 28.41 USD Million in the year 2024.
- Oncology is the Fastest growing segment in France Blood Screening Market to 2032 with a Growth rate of 13.71 % in forecast period 2025-2032.
-
France Blood Screening Market to 2032, By End User
- Diagnostic Centers is the largest segment in France Blood Screening Market to 2032 with a revenue of 32.21 USD Million in the year 2024.
- Diagnostic Centers is the Fastest growing segment in France Blood Screening Market to 2032 with a Growth rate of 13.68 % in forecast period 2025-2032.
-
France Blood Screening Market to 2032, By Products & Services
- Reagents & Kits is the largest segment in France Blood Screening Market to 2032 with a revenue of 51.46 USD Million in the year 2024.
- Instruments is the Fastest growing segment in France Blood Screening Market to 2032 with a Growth rate of 12.50 % in forecast period 2025-2032.
-
France Blood Screening Market to 2032, By Technology
- Enzyme-Linked Immunosorbent Assay (ELISA) is the largest segment in France Blood Screening Market to 2032 with a revenue of 32.08 USD Million in the year 2024.
- Next-Generation Sequencing (NGS) is the Fastest growing segment in France Blood Screening Market to 2032 with a Growth rate of 12.83 % in forecast period 2025-2032.
France Blood Screening Market Company Share Analysis
| Company Name |
|
||
| INNOVUS PHARMACEUTICALS, INC. | |||
| Pfizer Inc. | |||
| Bayer AG | |||
| Cipla Inc. | |||
| GSK plc. | |||
France Blood Screening Market Geographical Sales Distribution, 2018-2032 USD Million
France Blood Screening Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The France Blood Screening Market is segmented based on Segmentation Disease Type,End User,Products & Services,Technology.
France Blood Screening Market was valued at USD 105.27(Revenue in USD Million) in 2022.
France Blood Screening Market is projected to grow at a CAGR of 12.73% during the forecast period of 2024 to 2032.
The Reagents & Kits segment is expected to dominate the France Blood Screening Market, holding a largest market share of 51.46 USD Million in 2024
France Blood Screening Market Scope
France Blood Screening Market Segmentation & Scope
Disease Type
- Others
- HIV/AIDS
- Respiratory Diseases
- Infectious Diseases
- Cholesterol
- Cold & Flu
- Diabetes Mellitus
- Oncology
End User
- Ambulatory Surgical Centers
- Clinics
- Hospitals
- Blood Bank
- Diagnostic Centers
Products & Services
- Software & Services
- Instruments
- Reagents & Kits
Technology
- Others
- Western Blot Assay
- Nucleic Acid Test
- Next-Generation Sequencing (NGS)
- Rapid Tests
- Enzyme-Linked Immunosorbent Assay (ELISA)
Frequently Asked Questions
The France Blood Screening Market is segmented based on Segmentation Disease Type,End User,Products & Services,Technology.
France Blood Screening Market was valued at USD 105.27(Revenue in USD Million) in 2022.
France Blood Screening Market is projected to grow at a CAGR of 12.73% during the forecast period of 2024 to 2032.
The estimated market value of the France Blood Screening Market for final year is USD 221.16 (USD Million).
France Blood Screening Market Company Profiling
Frequently Asked Questions
The France Blood Screening Market is segmented based on Segmentation Disease Type,End User,Products & Services,Technology.
France Blood Screening Market was valued at USD 105.27(Revenue in USD Million) in 2022.
France Blood Screening Market is projected to grow at a CAGR of 12.73% during the forecast period of 2024 to 2032.
The estimated market value of the France Blood Screening Market for final year is USD 221.16 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.